Ethinylestradiol/Chlormadinone acetate for use in Dermatological disorders

American Journal of Clinical Dermatology

Volumn 12, Issue SUPPL. 1, 2011, Pages 13-19

  Vázquez, Mercedes Gómez ^a   Amayuelas, Ramón Navarra ^a   Lamarca, Marta ^b   Baquedano, Laura ^b   Ruiz, Sebastián Romero ^c   Vilar Checa, Eduardo ^d   Iniesta, Maria D ^e  

^a Hospital Municipal de Badalona   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c HOSPITAL DE MÓSTOLES   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; MINOXIDIL;

ACNE; ADULT; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; DISEASE ASSOCIATION; DRUG TOLERABILITY; ERYTHEMA; FEMALE; GYNECOLOGICAL EXAMINATION; HIRSUTISM; HUMAN; MALE TYPE ALOPECIA; MENSTRUAL IRREGULARITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SEBORRHEA; SKIN DISEASE; SKIN EXAMINATION; SKIN IRRITATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 80052488882     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/1153875-s0-000000000-00000     Document Type: Article

References (36)

1. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009 Feb; 91 (2): 456-488
2. Scheinfeld N. A review of hormonal therapy for female pattern (androgenic) alopecia [Commentary]. Dermatol Online J 2008; 14 (3): 1
3. Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc 2003 Jun; 8 (1): 24-27 (Pubitemid 36900487)
4. Rivera R, Guerra-Tapia A. Manejo de la alopecia androgenetica en mujeres pomenopausicas. Actas Dermosifiliogr 2009; 99: 257-261 (Pubitemid 351729642)
5. Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011 Jan; 164 (1): 5-15
6. Futterweit W, Dunaif A, Yeh HC, et al. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. Journal of the American Academy of Dermatology 1988 Nov; 19 (5 Pt 1): 831-836 (Pubitemid 18260991)
7. Olsen EA. Female pattern hair loss. Journal of the American Academy of Dermatology 2001; 45 (3 (Suppl 1)): S70-s80 (Pubitemid 32783335)
8. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005 Dec 15; 353 (24): 2578-2588
9. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004 Oct; 18 (5): 737-754 (Pubitemid 40424608)
10. Wendelin DS, Pope DN, Mallory SB. Hypertrichosis. Journal of the American Academy of Dermatology 2003 Feb; 48 (2): 161-179; quiz 80-1 (Pubitemid 36236142)
11. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. "Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group". Fertil Steril 2004 Jan; 81 (1): 19-25
12. Oberemok SS, Shalita AR. Acne vulgaris, I: pathogenesis and diagnosis. Cutis 2002 Aug; 70 (2): 101-105 (Pubitemid 41757461)
13. Grünenthal GmbH. Belara®: highlights of the product's properties [product monograph]. Aachen: Grünenthal GmbH, 2001
14. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000 Aug; 21 (4): 347-362 (Pubitemid 32279644)
15. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology 2000 Nov; 43 (5 Pt 1): 768-776
16. Whiting DA, Waldstreicher J, Sanchez M, et al. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc 1999 Dec; 4 (3): 282-284 (Pubitemid 30085821)
17. Thai KE, Sinclair RD. Finasteride for female androgenetic alopecia. Br J Dermatol 2002 Oct; 147 (4): 812-813
18. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005 Mar; 152 (3): 466-473 (Pubitemid 40547120)
19. Peereboom-Wynia JD, van der Willigen AH, van Joost T, et al. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol 1989; 69 (5): 395-398 (Pubitemid 19226104)
20. Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2%vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002 Jun; 146 (6): 992-999 (Pubitemid 34779479)
21. Griffing G. Hirsutism Treatment & Management. 2010 [cited 2011 9 May]; Available from: http://emedicine.medscape.com/article/121038-treatment
22. DeVillez RL, Jacobs JP, Szpunar CA, et al. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol 1994 Mar; 130 (3): 303-307
23. Bayer plc. Dianette summary of product characteristics. 2010 [cited 2011 11 May]; Available from: http://www.medicines.org.uk/EMC/medicine/1814/SPC/ Dianette
24. Berson DS, Chalker DK, Harper JC, et al. Current concepts in the treatment of acne: report from a clinical roundtable. Cutis 2003 Jul; 72 (1 Suppl): 5-13
25. Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2009; (3): CD004425
26. Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2008 Apr; 22 (2): 261-274 (Pubitemid 351297553)
27. Brucker C, Hedon B, The HS, et al. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02mg ethinylestradiol and 2mg chlormadinone acetate administered in a 24/4-day regimen. Contraception 2010 Jun; 81 (6): 501-509
28. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008 Apr; 77 (4): 249-256
29. Plewig G, Cunliffe WJ, Binder N, et al. Efficacy of an oral contraceptive containing EE 0.03 mg andCMA2mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009 Jul; 80 (1): 25-33
30. Pushparajah DS, Rohm P, Hoschen K, et al. Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03mg/chlormadinone acetate 2 mg (Belara(R)): a 13-cycle, observational study in routine clinical practice. Clin Drug Investig 2011; 31 (2): 121-134
31. Sabatini R, Orsini G, Cagiano R, et al. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception 2007 Nov; 76 (5): 342-347 (Pubitemid 47600123)
32. Uras R, Orru M, Pani F, et al. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. Contraception 2010 Aug; 82 (2): 131-138
33. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) - an open-label, prospective, noncontrolled, office-based phase III study. Contraception 2008 May; 77 (5): 337-343
34. Shaw JC. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol 2002; 3 (8): 571-578 (Pubitemid 35252507)
35. Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a singleblind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203 (1): 38-44 (Pubitemid 32830529)
36. Guerra-Tapia A, Sancho B. Ethinylestradio/Chlormadione Acetate: dermatological benefits. Am J Clin Dermatol 2011; 12 (Suppl. 1): 3-11